SiRNA RSS Page 11

Filtered By:
Cancer: Lung Cancer

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 1667 results found since Jan 2013.

Gefitinib enhances the anti ‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H
Int J Oncol. 2022 Dec;61(6):146. doi: 10.3892/ijo.2022.5436. Epub 2022 Oct 7.ABSTRACTGefitinib is a sensitive and effective drug to treat non‑small‑cell lung cancer (NSCLC) carrying the somatic activating mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR). In the present study, a new mechanism of action of gefitinib in EGFR‑mutated NSCLC cells was discovered using in vitro co‑culture of NSCLC cells with peripheral blood mononuclear cells (PBMCs). Gefitinib significantly enhanced the cytotoxicity of PBMCs against NSCLC cells expressing mutated EGFR but not in cells expressing wild‑t...
Source: Cancer Control - October 7, 2022 Category: Cancer & Oncology Authors: Huihui Guo Xilin Zhang Shangzhi Xie Tianwei Chen Dong Xie Ying Cai Dawei Cui Liang Wang Wei Chen Xiang Wang Source Type: research

Hesperidin Inhibits the p53-MDMXInteraction-Induced Apoptosis of Non-Small-Cell Lung Cancer and Enhances the Antitumor Effect of Carboplatin
CONCLUSION: Hesperidin can inhibit lung cancer by inhibiting the interaction between p53 and MDMX. Moreover, the combination of hesperidin and carboplatin can inhibit the migration and invasion of lung cancer cell lines through p53 upregulation, thereby increasing the antitumor effect of carboplatin.PMID:36157229 | PMC:PMC9507700 | DOI:10.1155/2022/5308577
Source: Journal of Oncology - September 26, 2022 Category: Cancer & Oncology Authors: Yu Feng Hongjie Huo Qiong Tang Source Type: research

Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery
This study verifies the successful spray drying procedure of LNP-siRNA systems maintaining their integrity and mediating strong gene silencing efficiency on mRNA and protein levels both in vitro and ex vivo. The successful spray drying procedure of LNP-siRNA formulations in 5% lactose solution creates a novel siRNA-based therapy option to target respiratory diseases such as lung cancer, asthma, COPD, cystic fibrosis and viral infections.PMID:36126785 | DOI:10.1016/j.jconrel.2022.09.021
Source: Cancer Control - September 20, 2022 Category: Cancer & Oncology Authors: Christoph M Zimmermann Domizia Baldassi Karen Chan Nathan B P Adams Alina Neumann Diana Leidy Porras-Gonzalez Xin Wei Nikolaus Kneidinger Mircea Gabriel Stoleriu Gerald Burgstaller Dominik Witzigmann Paola Luciani Olivia M Merkel Source Type: research

Construction of PEI ‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
ConclusionOur constructed lipid nanoparticles of tumor targeted therapy gene siRNA combination had the ability to target cells in vitro and downregulate the expression of PD-L1, realizing the tumor-specific expression of immune-stimulating cytokines, which is a highly efficient and safe targeted therapy nano-vaccine.
Source: Thoracic Cancer - September 19, 2022 Category: Cancer & Oncology Authors: Guixue Yang, Dong Zhou, Yin Dai, Yanqi Li, Jiang Wu, Quanxing Liu, Xufeng Deng Tags: ORIGINAL ARTICLE Source Type: research

Experimental Study on Antitumor Activity of Gold Nanoparticles-Assisted Delivery of PD-L1 SiRNA in Non-Small Cell Lung Cancer
Source: Journal of Biomedical Nanotechnology - September 14, 2022 Category: Nanotechnology Authors: Zhang, Yong Gu, Minwei Tags: research-article Source Type: research

Upregulation of dual-specificity phosphatase-26 is required for transforming growth factor β1(TGFβ1)-induced Epithelial-mesenchymal transition in A549 and PANC1 cells
CONCLUSIONS: Data provided suggest that TGFβ1 modulates the expression of DUSP genes and that upregulation of DUSP26 may be required for TGFβ1-promoted EMT in A549 and PANC1 cells. Further studies should be carried out to elucidate the requirement of individual DUSPs in TGFβ1-associated EMT in tumor cells.PMID:36053282 | DOI:10.1007/s11033-022-07893-1
Source: Cancer Control - September 2, 2022 Category: Cancer & Oncology Authors: Sabire Guler Berrin Zik Abdullah Yalcin Source Type: research

ATF4/MYC Regulates MTHFD2 to Promote NSCLC Progression by Mediating Redox Homeostasis
CONCLUSIONS: ATF4 promoted high expression of MTHFD2 in NSCLC dependent on MYC.PMID:36051358 | PMC:PMC9425107 | DOI:10.1155/2022/7527996
Source: Disease Markers - September 2, 2022 Category: Laboratory Medicine Authors: Yixing Gao Lan Feng Luping Zhang Jianhui Geng Erlong Zhang Source Type: research

Upregulation of dual-specificity phosphatase-26 is required for transforming growth factor β1(TGFβ1)-induced Epithelial-mesenchymal transition in A549 and PANC1 cells
CONCLUSIONS: Data provided suggest that TGFβ1 modulates the expression of DUSP genes and that upregulation of DUSP26 may be required for TGFβ1-promoted EMT in A549 and PANC1 cells. Further studies should be carried out to elucidate the requirement of individual DUSPs in TGFβ1-associated EMT in tumor cells.PMID:36053282 | DOI:10.1007/s11033-022-07893-1
Source: Molecular Biology Reports - September 2, 2022 Category: Molecular Biology Authors: Sabire Guler Berrin Zik Abdullah Yalcin Source Type: research

Upregulation of dual-specificity phosphatase-26 is required for transforming growth factor β1(TGFβ1)-induced Epithelial-mesenchymal transition in A549 and PANC1 cells
CONCLUSIONS: Data provided suggest that TGFβ1 modulates the expression of DUSP genes and that upregulation of DUSP26 may be required for TGFβ1-promoted EMT in A549 and PANC1 cells. Further studies should be carried out to elucidate the requirement of individual DUSPs in TGFβ1-associated EMT in tumor cells.PMID:36053282 | DOI:10.1007/s11033-022-07893-1
Source: Mol Biol Cell - September 2, 2022 Category: Molecular Biology Authors: Sabire Guler Berrin Zik Abdullah Yalcin Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20